MTOR and ependymoma: Furthermore, additional immunohistochemistry studies of pediatric ependymomas tissue revealed that 20 out of 23 (87%) pediatric ependymomas were immunoreactive for phosphorylated S6, a biomarker that has been shown to be associated with response to mTOR pathway-targeted therapy.33,34